These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 17724740

  • 21. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC.
    Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T, Farkas A, Tolvaj G, Horváth G.
    Orv Hetil; 2006 Feb 19; 147(7):321-4. PubMed ID: 17489160
    [Abstract] [Full Text] [Related]

  • 24. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.
    J Viral Hepat; 2005 May 19; 12(3):283-91. PubMed ID: 15850469
    [Abstract] [Full Text] [Related]

  • 25. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Chen YC, Lu SN, Lin MC.
    Chang Gung Med J; 2007 May 19; 30(1):92-7. PubMed ID: 17477035
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B, Annese M, Bacca D, Francavilla R, Rizzo G, Barbarini G.
    Am J Gastroenterol; 1998 Dec 19; 93(12):2445-51. PubMed ID: 9860407
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C.
    Golstein PE, Delforge ML, Deviere J, Marcellin P.
    J Viral Hepat; 2004 Mar 19; 11(2):183-6. PubMed ID: 14996354
    [Abstract] [Full Text] [Related]

  • 30. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
    Dumortier J, Scoazec JY, Chevallier P, Boillot O.
    J Hepatol; 2004 Apr 19; 40(4):669-74. PubMed ID: 15030984
    [Abstract] [Full Text] [Related]

  • 31. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ, HCV Natural History Study Group.
    Am J Gastroenterol; 2005 Feb 19; 100(2):299-307. PubMed ID: 15667486
    [Abstract] [Full Text] [Related]

  • 32. [Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha].
    Drózdz W, Ziółkowska-Kochan M, Kozielewicz D, Dybowska D, Borkowska A, Halota W.
    Przegl Epidemiol; 2008 Feb 19; 62(1):93-100. PubMed ID: 18536230
    [Abstract] [Full Text] [Related]

  • 33. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
    Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, Wang PW.
    J Gastroenterol Hepatol; 2006 Jan 19; 21(1 Pt 2):319-26. PubMed ID: 16460494
    [Abstract] [Full Text] [Related]

  • 34. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C.
    Liver Int; 2007 Mar 19; 27(2):247-59. PubMed ID: 17311621
    [Abstract] [Full Text] [Related]

  • 35. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
    Glesby MJ, Bassett R, Alston-Smith B, Fichtenbaum C, Jacobson EL, Brass C, Owens S, Sulkowski M, Race EM, Sherman KE, AIDS Clinical Trials Group A5088 Protocol Team.
    J Infect Dis; 2005 Mar 01; 191(5):686-93. PubMed ID: 15688281
    [Abstract] [Full Text] [Related]

  • 36. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
    Carella C, Mazziotti G, Morisco F, Rotondi M, Cioffi M, Tuccillo C, Sorvillo F, Caporaso N, Amato G.
    Eur J Endocrinol; 2002 Jun 01; 146(6):743-9. PubMed ID: 12039693
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul 01; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
    Ray G, Pal S, Nayyar I, Dey S.
    Trop Gastroenterol; 2007 Jul 01; 28(3):109-12. PubMed ID: 18383998
    [Abstract] [Full Text] [Related]

  • 39. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G, Jessen H, Weitner L, Mutz A, Schranz D, Rockstroh JK, Kaad Study Group.
    J Infect; 2006 Jul 01; 53(1):36-42. PubMed ID: 16269184
    [Abstract] [Full Text] [Related]

  • 40. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
    Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, Bach N, Klion F, Tobias H, Antignano L, Brown RS, Gabbaizadeh D, Geders J, Levendoglu H.
    Am J Gastroenterol; 2004 Sep 01; 99(9):1700-5. PubMed ID: 15330905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.